A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13059-e13059 ◽  
Author(s):  
Mitsuhiko Iwamoto ◽  
Kosei Kimura ◽  
Satoru Tanaka ◽  
Daigo Yamamoto ◽  
Katsuhide Yoshidome ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Patient Reported Outcomes ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Patient Reported ◽  
Line Chemotherapy

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

2007 ◽  
Vol 134 (2) ◽  
pp. 125-135 ◽  
Author(s):  
Martina Baur ◽  
Allan T. van Oosterom ◽  
Véronique Diéras ◽  
Michele Tubiana-Hulin ◽  
R. Charles Coombes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer

1996 ◽  
Vol 10 (5) ◽  
pp. 504-521 ◽  
Author(s):  
Robert Launois ◽  
Jeanne Reboul-Marty ◽  
Bernadette Henry ◽  
Jacques Bonneterre
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Second Line ◽  
Utility Analysis ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document